Furthermore, a higher frequency of tumor relapse in patients from PUS10 low expression group was revealed (Fig. 1J) and Kaplan–Meier plotter analysis of the SRRSH RCC cohort disclosed that patients with decreased PUS10 expression had shorter disease free survival (Fig. 1K). Here, PUS10 is linked to renal cell carcinoma.